Pub Date : 2025-08-21Print Date: 2025-08-01DOI: 10.1530/JOE-25-0032
Jing Chen, Jing Lei, Ganggang Wang, Huiling Qin, Li Yang
Osteoporosis (OP) is a systemic osteopathy characterized by a decrease in bone density and mass. Human bone mesenchymal stem cells (hBMSCs) exhibit multidirectional differentiation potential and play a critical role in bone metabolism. Herein, we investigated the diagnostic potential of miR-127-3p in OP and elucidated its regulatory role in hBMSCs, thereby providing novel insights into the diagnosis and progression prediction of OP. The relative expression of miR-127-3p was measured via RT-qPCR analysis. ROC curve and logistic analysis were applied to identify the diagnostic value of miR-127-3p for OP. The CCK8 assay and flow cytometry were used to assess cell viability and apoptosis. A luciferase reporter assay was performed to assess the interaction between VAMP2 and miR-127-3p. The bone differentiation markers RUNX2, OCN, and OPN were assayed using RT-qPCR and western blotting. We observed that the expression of miR-127-3p was reduced in patients with OP, allowing it to effectively distinguish these patients from healthy individuals. Transfection with miR-127-3p mimic inhibited hBMSC apoptosis, increased cell viability, and increased RUNX2, OCN, and OPN levels. Furthermore, miR-127-3p regulated hBMSCs via targeting VAMP2. Overexpression of VAMP2 reversed the effects of miR-127-3p on apoptosis, cell viability, and bone differentiation. In conclusion, these findings suggest that miR-127-3p may be a potential diagnostic tool for OP. In addition, miR-127-3p promotes hBMSC viability and differentiation through downregulating VAMP2; this decreases OP progression. Our findings will inform new ideas for the diagnosis and developmental prediction of OP.
{"title":"miR-127-3p regulates osteoporosis progression by targeting VAMP2 to modulate cell differentiation.","authors":"Jing Chen, Jing Lei, Ganggang Wang, Huiling Qin, Li Yang","doi":"10.1530/JOE-25-0032","DOIUrl":"10.1530/JOE-25-0032","url":null,"abstract":"<p><p>Osteoporosis (OP) is a systemic osteopathy characterized by a decrease in bone density and mass. Human bone mesenchymal stem cells (hBMSCs) exhibit multidirectional differentiation potential and play a critical role in bone metabolism. Herein, we investigated the diagnostic potential of miR-127-3p in OP and elucidated its regulatory role in hBMSCs, thereby providing novel insights into the diagnosis and progression prediction of OP. The relative expression of miR-127-3p was measured via RT-qPCR analysis. ROC curve and logistic analysis were applied to identify the diagnostic value of miR-127-3p for OP. The CCK8 assay and flow cytometry were used to assess cell viability and apoptosis. A luciferase reporter assay was performed to assess the interaction between VAMP2 and miR-127-3p. The bone differentiation markers RUNX2, OCN, and OPN were assayed using RT-qPCR and western blotting. We observed that the expression of miR-127-3p was reduced in patients with OP, allowing it to effectively distinguish these patients from healthy individuals. Transfection with miR-127-3p mimic inhibited hBMSC apoptosis, increased cell viability, and increased RUNX2, OCN, and OPN levels. Furthermore, miR-127-3p regulated hBMSCs via targeting VAMP2. Overexpression of VAMP2 reversed the effects of miR-127-3p on apoptosis, cell viability, and bone differentiation. In conclusion, these findings suggest that miR-127-3p may be a potential diagnostic tool for OP. In addition, miR-127-3p promotes hBMSC viability and differentiation through downregulating VAMP2; this decreases OP progression. Our findings will inform new ideas for the diagnosis and developmental prediction of OP.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-11Print Date: 2025-08-01DOI: 10.1530/JOE-24-0357
Rosiane Aparecida Miranda, Beatriz Souza da Silva, Iala Milene Bertasso, Luana Lopes de Souza, Edgar Mendes Souza Wan Der Maas, Jones Bernardes Graceli, Leandro Miranda-Alves, Egberto Gaspar de Moura, Patricia Cristina Lisboa
Graphical abstract:
Abstract: Tributyltin (TBT) is a toxic compound used in antifouling paints and known for its endocrine-disrupting properties, including female reproductive dysfunction. We hypothesized that TBT exposure during gestation and lactation induces long-term reproductive alterations in female offspring. Pregnant Wistar rats were orally exposed from gestational day 7 to the end of lactation to 0.01% ethanol (control), TBT 100 ng/kg, or TBT 1000 ng/kg body weight. Female offspring were evaluated at postnatal days (PND) 21, 45, and 180 for biometric, hormonal, and ovarian parameters. Birth weight was reduced in the TBT100ng group, and body weight was reduced by PND180 in the TBT1000ng group. At PND45, testosterone increased in both TBT groups, while FSH decreased in the TBT100ng group. Estrous cyclicity irregularities, such as a prolonged metestrus-diestrus phase, were noted in the TBT1000ng group. Ovarian analysis showed increased cystic and atretic follicles at PND21 and PND45. Reduction in primordial follicles (TBT100ng) and corpora lutea (both TBT groups) was observed at PND180, along with ovarian fibrosis. TBT exposure led to age- and dose-dependent disruptions in ovarian follicle dynamics: initial increases in healthy follicles at PND21, followed by elevated unhealthy follicles and reduced healthy ones at later stages. At PND21, both TBT doses increased ERα expression, while TBT100ng increased AR expression. These changes were accompanied by a persistent increase in ovarian mast cells and elevated IL-6 protein expression, particularly at PND21 and PND180. Thus, maternal TBT exposure disrupts ovarian development and function, potentially increasing susceptibility to abnormal conditions such as polycystic ovary syndrome and primary ovarian insufficiency later in life.
{"title":"Maternal exposure to tributyltin alters female reproductive system development.","authors":"Rosiane Aparecida Miranda, Beatriz Souza da Silva, Iala Milene Bertasso, Luana Lopes de Souza, Edgar Mendes Souza Wan Der Maas, Jones Bernardes Graceli, Leandro Miranda-Alves, Egberto Gaspar de Moura, Patricia Cristina Lisboa","doi":"10.1530/JOE-24-0357","DOIUrl":"10.1530/JOE-24-0357","url":null,"abstract":"<p><strong>Graphical abstract: </strong></p><p><strong>Abstract: </strong>Tributyltin (TBT) is a toxic compound used in antifouling paints and known for its endocrine-disrupting properties, including female reproductive dysfunction. We hypothesized that TBT exposure during gestation and lactation induces long-term reproductive alterations in female offspring. Pregnant Wistar rats were orally exposed from gestational day 7 to the end of lactation to 0.01% ethanol (control), TBT 100 ng/kg, or TBT 1000 ng/kg body weight. Female offspring were evaluated at postnatal days (PND) 21, 45, and 180 for biometric, hormonal, and ovarian parameters. Birth weight was reduced in the TBT100ng group, and body weight was reduced by PND180 in the TBT1000ng group. At PND45, testosterone increased in both TBT groups, while FSH decreased in the TBT100ng group. Estrous cyclicity irregularities, such as a prolonged metestrus-diestrus phase, were noted in the TBT1000ng group. Ovarian analysis showed increased cystic and atretic follicles at PND21 and PND45. Reduction in primordial follicles (TBT100ng) and corpora lutea (both TBT groups) was observed at PND180, along with ovarian fibrosis. TBT exposure led to age- and dose-dependent disruptions in ovarian follicle dynamics: initial increases in healthy follicles at PND21, followed by elevated unhealthy follicles and reduced healthy ones at later stages. At PND21, both TBT doses increased ERα expression, while TBT100ng increased AR expression. These changes were accompanied by a persistent increase in ovarian mast cells and elevated IL-6 protein expression, particularly at PND21 and PND180. Thus, maternal TBT exposure disrupts ovarian development and function, potentially increasing susceptibility to abnormal conditions such as polycystic ovary syndrome and primary ovarian insufficiency later in life.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-06Print Date: 2025-08-01DOI: 10.1530/JOE-25-0013
Julia Sánchez-Ceinos, Bethan C Townsend, Carmen Tercero-Alcázar, Jaime López-Alcalá, Ignacio Ortea, Salvador Morales-Conde, José L Pereira-Cunill, Pedro P García-Luna, David A Cano, María M Malagón, Rocío Guzmán-Ruiz
Bariatric surgery (BS) is the most effective treatment for obesity and its related comorbidities, resulting in significant adipose tissue (AT) loss and functional recovery. However, the molecular mechanisms in the AT that drive these health benefits remain poorly understood, and predictive factors for adequate weight loss are currently needed. This study aimed to identify the proteomic signature of subcutaneous AT (SAT) linked to BS-induced weight loss and metabolic improvement, and to determine potential predictors of individual response. Sequential window acquisition of all theoretical mass spectra (SWATH-MS) proteomics was performed on paired abdominal SAT samples from individuals with obesity before and after BS. Bioinformatic and correlation analyses were conducted between proteomic data and changes in anthropometric and clinical parameters. In addition, the effect of sera from BS participants on subcutaneous adipocytes was assessed in vitro. The SAT response to BS was characterised by an up-regulation of mitochondrial metabolism and a down-regulation of inflammation, which correlated with different anthropometric and circulating markers. Notably, obesity duration was associated with BS-induced weight loss. Individuals with short-standing obesity (SSO) exhibited greater proteomic remodelling, weight reduction, and clinical improvement post-BS than those with long-standing obesity (LSO). Furthermore, a regulatory axis involving miR-223-3p, glucose metabolism, and cytoskeleton reorganisation in adipocytes might be connected to the positive effects of BS in LSO. Overall, our results indicate that obesity duration is related to BS-induced weight loss through SAT proteomic remodelling. Addressing this relationship could help develop new strategies to enhance weight management and metabolic health in people living with obesity.
{"title":"Obesity duration is linked to bariatric surgery outcomes via adipose tissue response.","authors":"Julia Sánchez-Ceinos, Bethan C Townsend, Carmen Tercero-Alcázar, Jaime López-Alcalá, Ignacio Ortea, Salvador Morales-Conde, José L Pereira-Cunill, Pedro P García-Luna, David A Cano, María M Malagón, Rocío Guzmán-Ruiz","doi":"10.1530/JOE-25-0013","DOIUrl":"10.1530/JOE-25-0013","url":null,"abstract":"<p><p>Bariatric surgery (BS) is the most effective treatment for obesity and its related comorbidities, resulting in significant adipose tissue (AT) loss and functional recovery. However, the molecular mechanisms in the AT that drive these health benefits remain poorly understood, and predictive factors for adequate weight loss are currently needed. This study aimed to identify the proteomic signature of subcutaneous AT (SAT) linked to BS-induced weight loss and metabolic improvement, and to determine potential predictors of individual response. Sequential window acquisition of all theoretical mass spectra (SWATH-MS) proteomics was performed on paired abdominal SAT samples from individuals with obesity before and after BS. Bioinformatic and correlation analyses were conducted between proteomic data and changes in anthropometric and clinical parameters. In addition, the effect of sera from BS participants on subcutaneous adipocytes was assessed in vitro. The SAT response to BS was characterised by an up-regulation of mitochondrial metabolism and a down-regulation of inflammation, which correlated with different anthropometric and circulating markers. Notably, obesity duration was associated with BS-induced weight loss. Individuals with short-standing obesity (SSO) exhibited greater proteomic remodelling, weight reduction, and clinical improvement post-BS than those with long-standing obesity (LSO). Furthermore, a regulatory axis involving miR-223-3p, glucose metabolism, and cytoskeleton reorganisation in adipocytes might be connected to the positive effects of BS in LSO. Overall, our results indicate that obesity duration is related to BS-induced weight loss through SAT proteomic remodelling. Addressing this relationship could help develop new strategies to enhance weight management and metabolic health in people living with obesity.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-05Print Date: 2025-08-01DOI: 10.1530/JOE-24-0379
Mariana de Souza Pomacena, Patrícia Cristina Lisboa, Egberto Gaspar de Moura, Rosiane Aparecida Miranda
Over the years, environmental exposure to pesticides has significantly increased. Several new pesticides are being developed and approved for use, although their full impact on health and the environment remains unclear. Pesticides interfere with the endocrine system by acting on hormonal pathways, including hormone-receptor interactions and hormonal metabolism. Concomitant with the increasing use of endocrine-disrupting chemical molecules, reduced fertility and reproductive alterations in men and women have attracted increasing attention in recent years. Given the potential of pesticides to impact the reproductive system significantly, we conducted a narrative review of relevant animal studies, including those conducted on humans, and in vitro models exploring changes in the male and female reproductive systems associated with exposure to various pesticide classes, such as organochlorines, organophosphates, pyrethroids, carbamates, and neonicotinoids. Key dysfunctions reported primarily in different experimental models include alterations in the hypothalamic-pituitary-gonadal axis, morphological changes in the ovaries and testes, increased numbers of atretic follicles, and reduced sperm motility. Although research in this area has increased, important gaps remain, including inconsistencies in findings, lack of long-term human exposure studies, and limited understanding of the synergistic effects of pesticide formulations. It is crucial to emphasize the impact of pesticide exposure on fertility and encourage further research to elucidate the pathophysiological, morphological, and molecular mechanisms involved, as well as the effects of exposure to mixtures of these pesticides, mimicking the human exposome.
{"title":"Impact of pesticides on reproductive health: insights from animal and in vitro models in both sexes.","authors":"Mariana de Souza Pomacena, Patrícia Cristina Lisboa, Egberto Gaspar de Moura, Rosiane Aparecida Miranda","doi":"10.1530/JOE-24-0379","DOIUrl":"10.1530/JOE-24-0379","url":null,"abstract":"<p><p>Over the years, environmental exposure to pesticides has significantly increased. Several new pesticides are being developed and approved for use, although their full impact on health and the environment remains unclear. Pesticides interfere with the endocrine system by acting on hormonal pathways, including hormone-receptor interactions and hormonal metabolism. Concomitant with the increasing use of endocrine-disrupting chemical molecules, reduced fertility and reproductive alterations in men and women have attracted increasing attention in recent years. Given the potential of pesticides to impact the reproductive system significantly, we conducted a narrative review of relevant animal studies, including those conducted on humans, and in vitro models exploring changes in the male and female reproductive systems associated with exposure to various pesticide classes, such as organochlorines, organophosphates, pyrethroids, carbamates, and neonicotinoids. Key dysfunctions reported primarily in different experimental models include alterations in the hypothalamic-pituitary-gonadal axis, morphological changes in the ovaries and testes, increased numbers of atretic follicles, and reduced sperm motility. Although research in this area has increased, important gaps remain, including inconsistencies in findings, lack of long-term human exposure studies, and limited understanding of the synergistic effects of pesticide formulations. It is crucial to emphasize the impact of pesticide exposure on fertility and encourage further research to elucidate the pathophysiological, morphological, and molecular mechanisms involved, as well as the effects of exposure to mixtures of these pesticides, mimicking the human exposome.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-26Print Date: 2025-07-01DOI: 10.1530/JOE-24-0374
S Nirenjen, S Ankul Singh, R F Begum, E Arun, C Vellapandian, J Narayanan
Endocrine disruptors (EDs) are exogenous substances that interfere with the endocrine system, leading to adverse health outcomes. These substances, prevalent in industrial pollutants, pesticides, plastics, and personal care products, significantly impact hormonal regulation and disrupt various physiological processes. This review explores the sources and health impacts of EDs, focusing on their interference with hormonal axes, fetal development, and adipose tissue function. It highlights underlying mechanisms such as epigenetic modifications and discusses strategies to reduce ED exposure. Recent research reveals that EDs affect estrogen, androgen, and thyroid hormone signaling, contributing to developmental, reproductive, and metabolic disorders. Their interference with hormonal regulation is linked to abnormalities during fetal development and obesity through altered adipogenesis-related gene expression. Mechanisms such as DNA methylation, hypoxia-inducible factor signaling, and histone modifications play pivotal roles in ED-induced disruptions. Addressing ED exposure requires a multifaceted approach, incorporating lifestyle changes and public health initiatives to mitigate risks. Continued research is essential to better understand their effects and develop effective strategies for reducing their impact.
{"title":"Exploring the impact of endocrine disruptors on hormonal regulation and adipose tissue in health and obesity.","authors":"S Nirenjen, S Ankul Singh, R F Begum, E Arun, C Vellapandian, J Narayanan","doi":"10.1530/JOE-24-0374","DOIUrl":"10.1530/JOE-24-0374","url":null,"abstract":"<p><p>Endocrine disruptors (EDs) are exogenous substances that interfere with the endocrine system, leading to adverse health outcomes. These substances, prevalent in industrial pollutants, pesticides, plastics, and personal care products, significantly impact hormonal regulation and disrupt various physiological processes. This review explores the sources and health impacts of EDs, focusing on their interference with hormonal axes, fetal development, and adipose tissue function. It highlights underlying mechanisms such as epigenetic modifications and discusses strategies to reduce ED exposure. Recent research reveals that EDs affect estrogen, androgen, and thyroid hormone signaling, contributing to developmental, reproductive, and metabolic disorders. Their interference with hormonal regulation is linked to abnormalities during fetal development and obesity through altered adipogenesis-related gene expression. Mechanisms such as DNA methylation, hypoxia-inducible factor signaling, and histone modifications play pivotal roles in ED-induced disruptions. Addressing ED exposure requires a multifaceted approach, incorporating lifestyle changes and public health initiatives to mitigate risks. Continued research is essential to better understand their effects and develop effective strategies for reducing their impact.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-17Print Date: 2025-07-01DOI: 10.1530/JOE-25-0072
Shashank Tripathi, Shweta Maurya, Ajit Singh
Hyperglycemia is the predominant endocrine and metabolic disorder, resulting in infertility in males. Adropin, a hepatokine, is a well-known insulin sensitizer that regulates glucose and lipid homeostasis. Our recent reports demonstrated the vital role of adropin in the regulation of testicular activity, but its role in testicular function during pathological conditions such as hyperglycemia has not yet been studied. Therefore, this study aimed to explore the effect of adropin treatment on reproductive and metabolic dysfunctions in hyperglycemic mice. Hyperglycemia was induced by streptozotocin (55 mg/kg body weight; i.p.) treatment followed by treatment with either adropin (450 nmol/kg body weight; i.p.) or metformin (500 mg/kg body weight; orally) for a period of 15 days. Treatment of hyperglycemic mice enhanced insulin sensitivity by increasing insulin receptor expression in the testis and decreasing HOMA-IR and circulating glucose level. Adropin treatment of hyperglycemic mice increased the production of testicular testosterone by promoting the expression of steroidogenic proteins. Moreover, adropin treatment also enhanced the proliferation and survival of testicular germ cells by increasing PCNA expression and decreasing BAX/Bcl2 ratio and TUNEL-positive cells in the testis of hyperglycemic mice. Flow cytometric analysis revealed an increased number of advanced germ cells in adropin-treated hyperglycemic mice. Notably, adropin treatment was more effective than metformin in restoring reproductive functions in hyperglycemic mice, as evidenced by the reestablishment of the testicular histoarchitecture and increased synthesis of testosterone in the testes. These findings suggest that adropin may serve as a viable therapeutic alternative to mitigate hyperglycemia-associated testicular dysfunction.
{"title":"Adropin mitigates reproductive and metabolic dysfunctions in streptozotocin induced hyperglycemic mice.","authors":"Shashank Tripathi, Shweta Maurya, Ajit Singh","doi":"10.1530/JOE-25-0072","DOIUrl":"10.1530/JOE-25-0072","url":null,"abstract":"<p><p>Hyperglycemia is the predominant endocrine and metabolic disorder, resulting in infertility in males. Adropin, a hepatokine, is a well-known insulin sensitizer that regulates glucose and lipid homeostasis. Our recent reports demonstrated the vital role of adropin in the regulation of testicular activity, but its role in testicular function during pathological conditions such as hyperglycemia has not yet been studied. Therefore, this study aimed to explore the effect of adropin treatment on reproductive and metabolic dysfunctions in hyperglycemic mice. Hyperglycemia was induced by streptozotocin (55 mg/kg body weight; i.p.) treatment followed by treatment with either adropin (450 nmol/kg body weight; i.p.) or metformin (500 mg/kg body weight; orally) for a period of 15 days. Treatment of hyperglycemic mice enhanced insulin sensitivity by increasing insulin receptor expression in the testis and decreasing HOMA-IR and circulating glucose level. Adropin treatment of hyperglycemic mice increased the production of testicular testosterone by promoting the expression of steroidogenic proteins. Moreover, adropin treatment also enhanced the proliferation and survival of testicular germ cells by increasing PCNA expression and decreasing BAX/Bcl2 ratio and TUNEL-positive cells in the testis of hyperglycemic mice. Flow cytometric analysis revealed an increased number of advanced germ cells in adropin-treated hyperglycemic mice. Notably, adropin treatment was more effective than metformin in restoring reproductive functions in hyperglycemic mice, as evidenced by the reestablishment of the testicular histoarchitecture and increased synthesis of testosterone in the testes. These findings suggest that adropin may serve as a viable therapeutic alternative to mitigate hyperglycemia-associated testicular dysfunction.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-12Print Date: 2025-07-01DOI: 10.1530/JOE-25-0048
Breanne M Barrow, Pandora L Wander, Sakeneh Zraika
Statins are the most commonly used cholesterol-lowering medications, with proven efficacy in reducing cardiovascular disease in humans; however, statins are associated with a higher risk of new-onset type 2 diabetes (T2D). Mechanisms contributing to statin-induced diabetes are not well understood and may include effects on body composition, tissue insulin sensitivity, and/or pancreatic β-cell function. Given the essential role of the β-cell in maintaining normoglycemia, this review focuses on how statins may lead to the demise of the β-cell. We revisit what is known about the impact of statins on inhibition of the mevalonate pathway, including blockade of the synthesis of cholesterol and non-cholesterol products. We discuss aberrant expression of key β-cell genes and proteins, as well as dysregulation of β-cell components that facilitate normal insulin secretion, e.g., mitochondria and calcium channels. Importantly, we highlight areas that are understudied, including how statins alter cholesterol transport and metabolism in the β-cell, and the role of sex/gender in statin-induced β-cell dysfunction. As the number of statin users increases, there is an urgent need to address these gaps in our knowledge in order to shed light on strategies that limit statin-induced T2D.
{"title":"From cholesterol to glucose: uncovering how statins induce β-cell dysfunction to promote type 2 diabetes.","authors":"Breanne M Barrow, Pandora L Wander, Sakeneh Zraika","doi":"10.1530/JOE-25-0048","DOIUrl":"10.1530/JOE-25-0048","url":null,"abstract":"<p><p>Statins are the most commonly used cholesterol-lowering medications, with proven efficacy in reducing cardiovascular disease in humans; however, statins are associated with a higher risk of new-onset type 2 diabetes (T2D). Mechanisms contributing to statin-induced diabetes are not well understood and may include effects on body composition, tissue insulin sensitivity, and/or pancreatic β-cell function. Given the essential role of the β-cell in maintaining normoglycemia, this review focuses on how statins may lead to the demise of the β-cell. We revisit what is known about the impact of statins on inhibition of the mevalonate pathway, including blockade of the synthesis of cholesterol and non-cholesterol products. We discuss aberrant expression of key β-cell genes and proteins, as well as dysregulation of β-cell components that facilitate normal insulin secretion, e.g., mitochondria and calcium channels. Importantly, we highlight areas that are understudied, including how statins alter cholesterol transport and metabolism in the β-cell, and the role of sex/gender in statin-induced β-cell dysfunction. As the number of statin users increases, there is an urgent need to address these gaps in our knowledge in order to shed light on strategies that limit statin-induced T2D.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-04Print Date: 2025-07-01DOI: 10.1530/JOE-24-0283
Sekar Galuh, Erin Faught, Ingeborg Klaassen, Lisa L Koorneef, Joost Brinks, Elon H C van Dijk, Dirk Elewaut, Reinier O Schlingemann, Marcel J M Schaaf, Camiel J F Boon, Onno C Meijer
The glucocorticoid receptor (GR) mediates many activating and repressive effects of glucocorticoids in multiple contexts. Glucocorticoids can robustly induce the transcriptionally active protein Zinc finger and BTB domain containing 16 (ZBTB16). We evaluated how cortisol-induced ZBTB16, in turn, affects various GR-mediated actions in human cells and in zebrafish. We found that prevention of ZBTB16 induction led to potentiated GR-dependent effects on the human endothelial cell barrier and blood glucose levels in zebrafish larvae. In contrast, zbtb16 functional knockout abolished the GR-dependent effects on the inflammatory response in zebrafish larvae. At the mRNA level, zbtb16 knockdown potentiated transactivation and attenuated transrepression in a subset of GR target genes. Finally, ZBTB16 protein was strongly induced by dexamethasone in fibroblast-like synoviocytes derived from osteoarthritis patients. The data suggest that cortisol-induced ZBTB16 acts as an intracellular modulator of glucocorticoid action by limiting GR-mediated activating effects and enhancing repressive effects. This mechanism may facilitate a return to the initial cellular state after (proinflammatory) stimulation and enhance GR's anti-inflammatory effects. This mechanism is similar to that of 'dissociated' GR ligands and may guide drug development that aims to reduce side effects while retaining the clinical benefits of glucocorticoid treatment.
{"title":"The glucocorticoid receptor is affected by its target ZBTB16 in a dissociated manner.","authors":"Sekar Galuh, Erin Faught, Ingeborg Klaassen, Lisa L Koorneef, Joost Brinks, Elon H C van Dijk, Dirk Elewaut, Reinier O Schlingemann, Marcel J M Schaaf, Camiel J F Boon, Onno C Meijer","doi":"10.1530/JOE-24-0283","DOIUrl":"10.1530/JOE-24-0283","url":null,"abstract":"<p><p>The glucocorticoid receptor (GR) mediates many activating and repressive effects of glucocorticoids in multiple contexts. Glucocorticoids can robustly induce the transcriptionally active protein Zinc finger and BTB domain containing 16 (ZBTB16). We evaluated how cortisol-induced ZBTB16, in turn, affects various GR-mediated actions in human cells and in zebrafish. We found that prevention of ZBTB16 induction led to potentiated GR-dependent effects on the human endothelial cell barrier and blood glucose levels in zebrafish larvae. In contrast, zbtb16 functional knockout abolished the GR-dependent effects on the inflammatory response in zebrafish larvae. At the mRNA level, zbtb16 knockdown potentiated transactivation and attenuated transrepression in a subset of GR target genes. Finally, ZBTB16 protein was strongly induced by dexamethasone in fibroblast-like synoviocytes derived from osteoarthritis patients. The data suggest that cortisol-induced ZBTB16 acts as an intracellular modulator of glucocorticoid action by limiting GR-mediated activating effects and enhancing repressive effects. This mechanism may facilitate a return to the initial cellular state after (proinflammatory) stimulation and enhance GR's anti-inflammatory effects. This mechanism is similar to that of 'dissociated' GR ligands and may guide drug development that aims to reduce side effects while retaining the clinical benefits of glucocorticoid treatment.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paula Urones, Paula Juiz-Valiña, Elena Outeiriño-Blanco, María Jesús García-Brao, Vanesa Balboa-Barreiro, Fernando Cordido, Susana Sangiao-Alvarellos
Bariatric surgery (BS) is the most effective long-term approach for weight loss and improvement of obesity-related comorbidities. Growth differentiation factor 15 (GDF15), a cytokine that enhances insulin sensitivity and reduces food intake, is a promising therapeutic target for obesity. This study assessed changes in circulating GDF15 levels in obesity and following BS, examining their associations with anthropometric, clinical, and biochemical parameters. Circulating GDF15 levels were measured in normal-weight individuals and patients with obesity before BS and at 3, 6 and 12 months post-surgery. Correlation analyses and linear mixed models were used to investigate variations in circulating GDF15 levels and to identify variables associated with GDF15 concentration. Circulating GDF15 levels were elevated in patients with obesity compared to normal-weight individuals and were higher in men than in women. In the combined cohort of obese and normal-weight individuals, circulating GDF15 levels positively correlated with weight, BMI, fat mass, glucose markers, C-reactive protein, transaminases, triglycerides, urea, creatinine and uric acid, and negatively correlated with apolipoprotein A and total, HDL and LDL cholesterol. In the obese cohort, however, circulating GDF15 levels showed a negative correlation with fat mass, while other associations persisted. After BS, circulating GDF15 levels significantly decreased, particularly in patients with hypertension or type 2 diabetes (T2D). One year post-surgery, ΔGDF15 was negatively associated with BMI and positively with excess weight loss and excess BMI loss. In conclusion, BS significantly reduces circulating GDF15 levels, particularly in patients with hypertension or T2D, indicating an association with clinical improvement after BS.
{"title":"Relevance of GDF15 as a biomarker for clinical outcomes after bariatric surgery.","authors":"Paula Urones, Paula Juiz-Valiña, Elena Outeiriño-Blanco, María Jesús García-Brao, Vanesa Balboa-Barreiro, Fernando Cordido, Susana Sangiao-Alvarellos","doi":"10.1530/JOE-25-0010","DOIUrl":"10.1530/JOE-25-0010","url":null,"abstract":"<p><p>Bariatric surgery (BS) is the most effective long-term approach for weight loss and improvement of obesity-related comorbidities. Growth differentiation factor 15 (GDF15), a cytokine that enhances insulin sensitivity and reduces food intake, is a promising therapeutic target for obesity. This study assessed changes in circulating GDF15 levels in obesity and following BS, examining their associations with anthropometric, clinical, and biochemical parameters. Circulating GDF15 levels were measured in normal-weight individuals and patients with obesity before BS and at 3, 6 and 12 months post-surgery. Correlation analyses and linear mixed models were used to investigate variations in circulating GDF15 levels and to identify variables associated with GDF15 concentration. Circulating GDF15 levels were elevated in patients with obesity compared to normal-weight individuals and were higher in men than in women. In the combined cohort of obese and normal-weight individuals, circulating GDF15 levels positively correlated with weight, BMI, fat mass, glucose markers, C-reactive protein, transaminases, triglycerides, urea, creatinine and uric acid, and negatively correlated with apolipoprotein A and total, HDL and LDL cholesterol. In the obese cohort, however, circulating GDF15 levels showed a negative correlation with fat mass, while other associations persisted. After BS, circulating GDF15 levels significantly decreased, particularly in patients with hypertension or type 2 diabetes (T2D). One year post-surgery, ΔGDF15 was negatively associated with BMI and positively with excess weight loss and excess BMI loss. In conclusion, BS significantly reduces circulating GDF15 levels, particularly in patients with hypertension or T2D, indicating an association with clinical improvement after BS.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Androgen excess is thought to play a crucial role in the onset and progression of polycystic ovary syndrome (PCOS), although the underlying mechanism remains unclear. Using our mild dihydrotestosterone (DHT)-exposed rat model, which more closely reproduces human PCOS phenotypes than conventional models, we examined whether the presence of ovaries is essential in the pathophysiology of PCOS induced by androgen excess. At 26 days of age, female rats were divided into two primary groups: bilaterally ovariectomized (OVX) and sham-operated (intact). Each group was further divided into PCOS (implanted with a tube filled with diluted DHT) and control (implanted with an empty tube) groups. Body weight and food intake were measured weekly. At 58 and 59 days of age, locomotor activity and body temperature were measured. At 87 days of age, brain, blood, and fat tissues were collected and analyzed. Body weight, food intake, adipocyte size, weight of visceral and subcutaneous fat, and serum leptin levels were higher in the intact-PCOS group than the intact-control group, but there were no significant differences between the OVX-PCOS and OVX-control groups. In the intact-PCOS group, compared with the intact-control group, locomotor activity was significantly lower, particularly in the light phase, and body temperature was significantly higher in the darkness phase, whereas there were no significant differences between the OVX-PCOS and OVX-control groups. The effects of androgen might depend on the estrogen milieu, suggesting that the presence of ovaries is essential in the pathophysiologic development and progression of androgen-induced PCOS.
{"title":"Reduced locomotor activity in an ovarian-intact rat model of PCOS induced by mild exposure to dihydrotestosterone.","authors":"Hiroki Noguchi, Yuri Yamamoto, Moeka Arata, Nariho Nakamura, Erika Yamanaka, Kou Tamura, Hidenori Aoki, Asuka Takeda, Saki Minato, Hiroaki Inui, Riyo Kinouchi, Kanako Yoshida, Toshiya Matsuzaki, Takeshi Iwasa","doi":"10.1530/JOE-24-0348","DOIUrl":"10.1530/JOE-24-0348","url":null,"abstract":"<p><p>Androgen excess is thought to play a crucial role in the onset and progression of polycystic ovary syndrome (PCOS), although the underlying mechanism remains unclear. Using our mild dihydrotestosterone (DHT)-exposed rat model, which more closely reproduces human PCOS phenotypes than conventional models, we examined whether the presence of ovaries is essential in the pathophysiology of PCOS induced by androgen excess. At 26 days of age, female rats were divided into two primary groups: bilaterally ovariectomized (OVX) and sham-operated (intact). Each group was further divided into PCOS (implanted with a tube filled with diluted DHT) and control (implanted with an empty tube) groups. Body weight and food intake were measured weekly. At 58 and 59 days of age, locomotor activity and body temperature were measured. At 87 days of age, brain, blood, and fat tissues were collected and analyzed. Body weight, food intake, adipocyte size, weight of visceral and subcutaneous fat, and serum leptin levels were higher in the intact-PCOS group than the intact-control group, but there were no significant differences between the OVX-PCOS and OVX-control groups. In the intact-PCOS group, compared with the intact-control group, locomotor activity was significantly lower, particularly in the light phase, and body temperature was significantly higher in the darkness phase, whereas there were no significant differences between the OVX-PCOS and OVX-control groups. The effects of androgen might depend on the estrogen milieu, suggesting that the presence of ovaries is essential in the pathophysiologic development and progression of androgen-induced PCOS.</p>","PeriodicalId":15740,"journal":{"name":"Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}